ETV2 Transcription Factor for Vascular Endothelial Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic cardiovascular disease, including stem cell therapies, face limitations such as low effectiveness, potential tumor formation, and reliance on animal components, as well as inefficient differentiation of adult stem cells into vascular endothelial cells, which hinder effective blood-vessel regeneration.
Innovation Solution
The use of an ETV2 transcription factor, combined with a polyamide DNA binding domain, nuclear localization signal peptide, and nano-particles, allows direct reprogramming of fibroblasts into vascular endothelial cells without a pluripotent state, overcoming previous methods' insertional mutation risks and improving delivery efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adult stem cells are used for blood-vessel regeneration treatment, then the treatment can be applied clinically, but the therapeutic effect is insufficient due to low differentiation ability into vascular endothelial cells
Solution Approach 1:
The patent changes the molecular parameters of the stem cells by introducing and overexpressing the ETV2 transcription factor. This parameter change (gene expression level) directly transforms the differentiation capability of adult stem cells, enabling them to efficiently differentiate into vascular endothelial cells while maintaining their adult stem cell status
Solution Approach 2:
The ETV2 transcription factor serves as an intermediary that mediates the transformation from adult stem cells to vascular endothelial cells. Instead of directly inducing differentiation through complex signaling pathways, the patent uses ETV2 as a molecular mediator that directly binds to DNA and activates vascular endothelial cell-specific genes, thereby achieving efficient differentiation
2Productivity
If pluripotent stem cells are used for blood-vessel regeneration, then differentiation into vascular endothelial cells is improved, but the risk of tumor formation and abnormal tissue development increases
Solution Approach 1:
The patent extracts only the essential function of pluripotent stem cells (differentiation into vascular endothelial cells) by introducing the key transcription factor ETV2 into adult stem cells. This extraction approach separates the beneficial differentiation capability from the harmful tumorigenic potential inherent in pluripotent stem cells
Solution Approach 2:
The patent creates a functional copy of the ETV2 transcription factor's role without using actual pluripotent stem cells. By introducing ETV2 into adult stem cells, the patent replicates the differentiation capability of pluripotent stem cells while using a safer cellular base that does not carry the same tumorigenic risks
3Productivity
If conventional gene injection methods (retrovirus or lentivirus) are used to overexpress transcription factor, then the transcription factor can be delivered into cells, but insertional mutation occurs in the genome causing safety issues
Solution Approach 1:
The patent replaces the mechanical integration mechanism of viral vectors with a non-integrating delivery system. Instead of using retrovirus or lentivirus that physically insert genetic material into the genome, the patent uses alternative delivery methods (such as plasmid transfection, protein transduction, or mRNA delivery) that achieve gene expression without genomic integration, thereby eliminating insertional mutation risks
Solution Approach 2:
The patent introduces ETV2 into cells using intermediary delivery systems rather than direct viral integration. These intermediaries (plasmids, proteins, or mRNA) temporarily deliver the genetic information without becoming permanently integrated into the host genome, thus achieving the desired gene expression while avoiding the harmful effects of viral insertion
Data Source
AI summary
Provided in the present specification is an ETV2 transcription factor comprising: a polyamide comprising a domain binding to DNA (DNA binding domain) of an ETV2 gene; a nuclear localization signal peptide; and a nano-particle.